Evidence map›Paper›PMID 28328316›Full record

ArticleSLAS discovery : advancing life sciences R & D2017

A High-Throughput Screening Assay Using a Photoconvertable Protein for Identifying Inhibitors of Transcription, Translation, or Proteasomal Degradation.

David K Heidary, Ashley Fox, Chris I Richards, Edith C Glazer

Open access · hybridAbstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

David K Heidary1 Department of Chemistry, University of Kentucky, Lexington, KY, USA.
Ashley Fox1 Department of Chemistry, University of Kentucky, Lexington, KY, USA.
Chris I Richards1 Department of Chemistry, University of Kentucky, Lexington, KY, USA.
Edith C Glazer1 Department of Chemistry, University of Kentucky, Lexington, KY, USA.
University of Kentucky · US

Funding

Training in Drug Abuse Related Research.T32DA016176 · NIDA · UNIVERSITY OF KENTUCKY · PI DWOSKIN, LINDA P · 2004 to 2020
$4.0M
Light-responsive ruthenium compounds for applications in diseaseR01GM107586 · NIGMS · UNIVERSITY OF KENTUCKY · PI GLAZER, EDITH C · 2014 to 2019
$1.7M
NIDA NIH HHS T32 DA016176NIGMS NIH HHS R01 GM107586
6 · The paper itself

Abstract

Dysregulated transcription, translation, and protein degradation are common features of cancer cells, regardless of specific genetic profiles. Several clinical anticancer agents take advantage of this characteristic vulnerability and interfere with the processes of transcription and translation or inhibit protein degradation. However, traditional assays that follow the process of protein production and removal require multistep processing and are not easily amenable to high-throughput screening. The use of recombinant fluorescent proteins provides a convenient solution to this problem, and moreover, photoconvertable fluorescent proteins allow for ratiometric detection of both new protein production and removal of existing proteins. Here, the photoconvertable protein Dendra2 is used in the development of in-cell assays of protein production and degradation that are optimized and validated for high-throughput screening. Conversion from the green to red emissive form can be achieved using a high-intensity light-emitting diode array, producing a stable pool of the red fluorescent form of Dendra2. This allows for rates of protein production or removal to be quantified in a plate reader or by fluorescence microscopy, providing a means to measure the potencies of inhibitors that affect these key processes.

Indexed as

High-Throughput Screening AssaysBortezomibCell LineGenes, ReporterGenetic VectorsHEK293 CellsHumansLuminescent ProteinsNF-KappaB Inhibitor alphaProteasome Endopeptidase ComplexProteasome InhibitorsProtein BiosynthesisProtein Synthesis InhibitorsProteolysisRecombinant Fusion ProteinsTranscription, GeneticBortezomibDendra2 protein, DendronephthyaLuminescent ProteinsNF-KappaB Inhibitor alphaProteasome Endopeptidase ComplexProteasome InhibitorsProtein Synthesis InhibitorsRecombinant Fusion Proteinscancer and cancer drugscell-based assaysfluorescence methodsmedicinal chemistryphenotypic drug discovery

Identifiers

PMID28328316
PMCPMC5526623
OpenAlexW2568623029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.